International real-world study of combination immunotherapy sequences in metastatic melanoma.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment, with programmed cell death protein 1 (PD-1) inhibitors-alone or in combination with cytotoxic T-lymphocyte-associated protein 4 or lymphocyte-activation gene 3 inhibitors-demonstrating significant efficacy. However, there is a critical lack of robust data to determine the optimal sequencing of these therapies for individual patients. In particular, the role of relatlimab+nivolumab (rela/nivo) within treatment sequences remains poorly defined. Choosing the right sequence is strategic, as an inappropriate order may compromise the effectiveness of subsequent treatments and limit long-term benefits.

Methods

This multicenter retrospective and prospective study evaluated 190 patients across thre

SUBMITTER: Guardamagna M 

PROVIDER: S-EPMC12666067 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature